

Stanford

Siri Strand

Research Engineer, Pathology Sponsored Projects #2

Publications

PUBLICATIONS

- **Single Cell Expression Analysis of Breast Precancers Identifies Alterations in Epithelial Integrity**
Qin, X., Strand, S., Lee, M., Zhu, C., Vennam, S., Varma, S., King, L., Rosenberger, L. H., Plichta, J. K., Hwang, E., Owzar, K., Marks, J. R., West, et al
SPRINGER.2024: S112
- **Chromatin insulation orchestrates matrix metalloproteinase gene cluster expression reprogramming in aggressive breast cancer tumors.** *Molecular cancer*
Llinàs-Arias, P., Ensenyat-Mendez, M., Íñiguez-Muñoz, S., Orozco, J. I., Valdez, B., Salomon, M. P., Matsuba, C., Solivellas-Pieras, M., Bedoya-López, A. F., Sesé, B., Mezger, A., Ormestad, M., Unzueta, et al
2023; 22 (1): 190
- **From the lab to the clinic: Lessons learned from a translational working group.**
Lynch, T., Basila, D., Schnitt, S. J., Marks, J. R., Strand, S. H., Hyslop, T., Badve, S. S., Watson, M. A., Le-Petross, H. T., Grimm, L., West, R. B., Weiss, A., Rapperport, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Characterizing N-glycan profiles of DCIS progression using tissue imaging MALDI mass spectrometry**
Wallace, E. N., Grimsley, G., Strand, S. H., Angelo, R., Colditz, G., Hwang, E., West, R., Marks, J. R., Angel, P. M., Drake, R. R.
AMER ASSOC CANCER RESEARCH.2022
- **Characterizing N-glycan profiles of DCIS progression using tissue imaging MALDI mass spectrometry.**
Wallace, E. N., Grimsley, G., Strand, S. H., Angelo, R., Colditz, G., Hwang, E., West, R., Marks, J. R., Angel, P. M., Drake, R. R.
AMER ASSOC CANCER RESEARCH.2022: 8-9
- **A SOX9-B7x axis safeguards dedifferentiated tumor cells from immunosurveillance to enable DCIS progression**
Wallace, E. N., Grimsley, G., Strand, S. H., Angelo, R., Colditz, G., Hwang, E., West, R., Marks, J. R., Angel, P. M., Drake, R. R.
AMER ASSOC CANCER RESEARCH.2022
- **Discrete regulation of the collagen proteome among pathological features in DCIS and invasive breast cancer by mass spectrometry tissue imaging**
Hulahan, T. S., Wallace, E. N., Strand, S. H., Angelo, R., Colditz, G., Hwang, E., West, R., Spruill, L., Marks, J. R., Drake, R. R., Angel, P. M.
AMER ASSOC CANCER RESEARCH.2022
- **Discrete regulation of the collagen proteome among pathological features in DCIS and invasive breast cancer by mass spectrometry tissue imaging**
Hulahan, T. S., Wallace, E. N., Strand, S. H., Angelo, R., Colditz, G., Hwang, E., West, R., Spruill, L., Marks, J. R., Drake, R. R., Angel, P. M.
AMER ASSOC CANCER RESEARCH.2022
- **Using clinical characteristics and molecular markers to predict the risk of subsequent ipsilateral breast events after excision of DCIS**
Colditz, G. A., Liu, Y., Strand, S. H., King, L., Marks, J., Maley, C., West, R. B., Hwang, E.
AMER ASSOC CANCER RESEARCH.2022
- **Using clinical characteristics and molecular markers to predict the risk of subsequent ipsilateral breast events after excision of DCIS**
Colditz, G. A., Liu, Y., Strand, S. H., King, L., Marks, J., Maley, C., West, R. B., Hwang, E.
AMER ASSOC CANCER RESEARCH.2022
- **Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts.** *Cancer cell*
Strand, S. H., Rivero-Gutierrez, B., Houlahan, K. E., Seoane, J. A., King, L. M., Risom, T., Simpson, L. A., Vennam, S., Khan, A., Cisneros, L., Hardman, T., Harmon, B., Couch, et al
2022

- **MITI minimum information guidelines for highly multiplexed tissue images.** *Nature methods*
Schapiro, D., Yapp, C., Sokolov, A., Reynolds, S. M., Chen, Y., Sudar, D., Xie, Y., Muhlich, J., Arias-Camison, R., Arena, S., Taylor, A. J., Nikolov, M., Tyler, et al
2022; 19 (3): 262-267
- **Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma.** *Cell*
Risom, T., Glass, D. R., Averbukh, I., Liu, C. C., Baranski, A., Kagel, A., McCaffrey, E. F., Greenwald, N. F., Rivero-Gutiérrez, B., Strand, S. H., Varma, S., Kong, A., Keren, et al
2022; 185 (2): 299-310.e18
- **The human tumor atlas network (HTAN) breast pre cancer atlas: A multi-omic integrative analysis of ductal carcinoma in situ (DCIS) and correlation with clinical outcomes**
Hwang, S., Strand, S. H., Rivero, B., King, L., Risom, T., Harmon, B., Couch, F., Gallagher, K., Kilgore, M., Wei, S., DeMichele, A., King, T., McAuliffe, et al
AMER ASSOC CANCER RESEARCH.2021
- **Mapping the tumor and microenvironmental evolution underlying DCIS progression through multiplexed ion beam imaging.**
Risom, T., Rivero, B., Liu, C., Baranski, A., Strand, S., Greenwald, N., McCaffrey, E., Varma, S., Keren, L., Srivastava, S., Zhu, C., Vennam, S., Hwang, et al
AMER ASSOC CANCER RESEARCH.2020
- **Validation of the four-miRNA biomarker panel MiCaP for prediction of long-term prostate cancer outcome** *SCIENTIFIC REPORTS*
Strand, S. H., Schmidt, L., Weiss, S., Borre, M., Kristensen, H., Rasmussen, A., Daugaard, T., Kristensen, G., Stroomberg, H., Roder, M., Brasso, K., Mouritzen, P., Sorensen, et al
2020; 10 (1): 10704
- **Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential** *CELLS*
Bjerre, M., Nørgaard, M., Larsen, O., Jensen, S., Strand, S. H., Ostergren, P., Fode, M., Fredsøe, J., Ulhøi, B., Mortensen, M., Jensen, J., Borre, M., Sorensen, et al
2020; 9 (6)
- **The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution.** *Cell*
Rozenblatt-Rosen, O., Regev, A., Oberdoerffer, P., Nawy, T., Hupalowska, A., Rood, J. E., Ashenberg, O., Cerami, E., Coffey, R. J., Demir, E., Ding, L., Esplin, E. D., Ford, et al
2020; 181 (2): 236–49
- **Elevated miR-615-3p Expression Predicts Adverse Clinical Outcome and Promotes Proliferation and Migration of Prostate Cancer Cells** *AMERICAN JOURNAL OF PATHOLOGY*
Laursen, E. B., Fredsøe, J., Schmidt, L., Strand, S. H., Kristensen, H., Rasmussen, A. I., Daugaard, T. F., Mouritzen, P., Hoyer, S., Kristensen, G., Stroomberg, H. V., Brasso, K., Roder, et al
2019; 189 (12): 2377–88
- **A novel combined miRNA and methylation marker panel (miMe) for prediction of prostate cancer outcome after radical prostatectomy.** *International journal of cancer*
Strand, S. H., Bavafaye-Haghghi, E., Kristensen, H., Rasmussen, A. K., Hoyer, S., Borre, M., Mouritzen, P., Besenbacher, S., Ørntoft, T. F., Sorensen, K. D.
2019
- **Aberrant DOCK2, GRASP, HIF3A and PKFP Hypermethylation has Potential as a Prognostic Biomarker for Prostate Cancer.** *International journal of molecular sciences*
Bjerre, M. T., Strand, S. H., Nørgaard, M., Kristensen, H., Rasmussen, A. K., Mortensen, M. M., Fredsøe, J., Mouritzen, P., Ulhøi, B., Ørntoft, T., Borre, M., Sørensen, K. D.
2019; 20 (5)
- **5hmC Level Predicts Biochemical Failure Following Radical Prostatectomy in Prostate Cancer Patients with ERG Negative Tumors.** *International journal of molecular sciences*
Kristensen, G., Strand, S. H., Røder, M. A., Berg, K. D., Toft, B. G., Høyer, S., Borre, M., Sørensen, K. D., Brasso, K.
2019; 20 (5)
- **Exploring the transcriptome of hormone-naïve multifocal prostate cancer and matched lymph node metastases.** *British journal of cancer*
Schmidt, L., Møller, M., Haldrup, C., Strand, S. H., Vang, S., Hedegaard, J., Høyer, S., Borre, M., Ørntoft, T., Sørensen, K. D.
2018; 119 (12): 1527-1537
- **Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients.** *Annals of oncology : official journal of the European Society for Medical Oncology*

- Schmidt, L., Fredsøe, J., Kristensen, H., Strand, S. H., Rasmussen, A., Hoyer, S., Borre, M., Mouritzen, P., Ørnloft, T., Sørensen, K. D.
2018; 29 (9): 2003-2009
- **Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer.** *Clinical epigenetics*
Storebjerg, T. M., Strand, S. H., Hoyer, S., Lynnerup, A. S., Borre, M., Ørnloft, T. F., Sørensen, K. D.
2018; 10 (1): 105
 - **Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies.** *Molecular oncology*
Haldrup, C., Pedersen, A. L., Øgaard, N., Strand, S. H., Hoyer, S., Borre, M., Ørnloft, T. F., Sørensen, K. D.
2018; 12 (4): 545-560
 - **RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy.** *Oncotarget*
Strand, S. H., Switnicki, M., Moller, M., Haldrup, C., Storebjerg, T. M., Hedegaard, J., Nordentoft, I., Hoyer, S., Borre, M., Pedersen, J. S., Wild, P. J., Park, J. Y., Ørnloft, et al
2017; 8 (4): 5774-5788
 - **Heterogeneous patterns of DNA methylation-based field effects in histologically normal prostate tissue from cancer patients.** *Scientific reports*
Møller, M., Strand, S. H., Mundbjerg, K., Liang, G., Gill, I., Haldrup, C., Borre, M., Hoyer, S., Ørnloft, T. F., Sørensen, K. D.
2017; 7: 40636
 - **HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer.** *Oncotarget*
Ross-Adams, H., Ball, S., Lawrenson, K., Halim, S., Russell, R., Wells, C., Strand, S. H., Ørnloft, T. F., Larson, M., Armasu, S., Massie, C. E., Asim, M., Mortensen, et al
2016; 7 (46): 74734-74746
 - **High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer.** *Clinical epigenetics*
Strand, S. H., Hoyer, S., Lynnerup, A. S., Haldrup, C., Storebjerg, T. M., Borre, M., Orntoft, T. F., Sorensen, K. D.
2015; 7: 111
 - **Prognostic DNA methylation markers for prostate cancer.** *International journal of molecular sciences*
Strand, S. H., Orntoft, T. F., Sorensen, K. D.
2014; 15 (9): 16544-76
 - **Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Kristensen, H., Haldrup, C., Strand, S., Mundbjerg, K., Mortensen, M. M., Thorsen, K., Ostenfeld, M. S., Wild, P. J., Arsov, C., Goering, W., Visakorpi, T., Egevad, L., Lindberg, et al
2014; 20 (8): 2169-81
 - **Prognostic significance of aberrantly silenced ANPEP expression in prostate cancer.** *British journal of cancer*
Sørensen, K. D., Abildgaard, M. O., Haldrup, C., Ulhøi, B. P., Kristensen, H., Strand, S., Parker, C., Hoyer, S., Borre, M., Ørnloft, T. F.
2013; 108 (2): 420-8

PRESENTATIONS

- High levels of 5-hydroxymethylcytosine (5hmC) predict Biochemical Recurrence after Prostatectomy in ERG Negative Prostate Cancer - American Association for Cancer Research Annual Meeting (April 2016)
- Prostate cancer biomarker development - Danish Biobank Network Annual meeting 2018 (January 2018)
- Genomewide profiling of the prostate cancer methylome for biomarker discovery - Oslo Prostate Cancer Symposium (5/2014)
- DNA methylation & cell line aggression models for prostate cancer biomarker discovery - MOLPROS annual meeting 2014 (1/1/2014)
- Genome-wide profiling of the prostate cancer methylome for biomarker discovery - American Association for Cancer Research Annual Meeting 2013 (January 2013)
- Prostate cancer biomarker discovery - MOLPROS annual meeting 2013 (1/2013)